Clearside Biomedical enters license agreement with Aura Biosciences
Clearside Biomedical announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside's Suprachoroidal Space Microinjectorto deliver Aura's proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma. Aura is developing a novel class of therapies, viral nanoparticle conjugates, designed to selectively bind and eliminate cancer cells without damaging surrounding normal tissues. Aura is licensing Clearside's proprietary SCS Microinjector as a potential non-surgical alternative to intravitreal delivery of Aura's proprietary anti-cancer drug candidates, which may enable the delivery of higher concentrations using a lower dose to the choroid and adjacent areas. If the collaboration proves successful following preclinical and proof-of-concept studies, Aura may utilize the SCS Microinjector for certain future development programs. Pursuant to the licensing agreement, Clearside is eligible to receive payments related to pre-specified development, regulatory and sales milestones, as well as royalties on product sales that utilize the SCS Microinjector.